Amphastar Pharmaceuticals, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Amphastar Pharmaceuticals, Inc. (AMPH) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $7.09 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- Amphastar Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $7.09M, a 11.09% increase year-over-year.
- Amphastar Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $9.27M, a 10.50% increase year-over-year.
- Amphastar Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $6.30M, a 12.53% increase year-over-year.
- Amphastar Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $6.38M, a 10.42% increase year-over-year.
- Amphastar Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $27.28M, a 11.94% increase from fiscal 2024.
- Amphastar Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $24.37M, a 20.38% increase from fiscal 2023.
- Amphastar Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $20.24M, a 13.34% increase from fiscal 2022.
- Amphastar Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $17.86M, a 0.08% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.09M 10-Q · filed 2026-08-06 | $16.36M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $9.27M 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $27.28M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $6.30M 10-Q · filed 2025-11-06 | $12.68M derived: sum of 2 quarters · filed 2026-08-06 | $21.07M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | $6.38M 10-Q · filed 2026-08-06 | $14.78M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $8.39M 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $24.37M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $5.60M 10-Q · filed 2025-11-06 | $11.38M derived: sum of 2 quarters · filed 2025-11-06 | $18.74M derived: sum of 3 quarters · filed 2025-11-06 | |
| 2024-06-30 | $5.78M 10-Q · filed 2025-11-06 | $13.14M derived: sum of 2 quarters · filed 2025-11-06 | ||
| 2024-03-31 | $7.36M 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $20.24M 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $4.64M 10-Q · filed 2024-11-07 | $9.51M derived: sum of 2 quarters · filed 2024-11-07 | $15.62M derived: sum of 3 quarters · filed 2024-11-07 | |
| 2023-06-30 | $4.87M 10-Q · filed 2024-11-07 | $10.98M derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | $6.11M 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | $17.86M 10-K · filed 2025-03-03 | |||
| 2022-09-30 | $4.30M 10-Q · filed 2023-11-08 | $8.53M derived: sum of 2 quarters · filed 2023-11-08 | $13.56M derived: sum of 3 quarters · filed 2023-11-08 | |
| 2022-06-30 | $4.24M 10-Q · filed 2023-11-08 | $9.26M derived: sum of 2 quarters · filed 2023-11-08 | ||
| 2022-03-31 | $5.02M 10-Q · filed 2023-11-08 | |||
| 2021-12-31 | $17.84M 10-K · filed 2024-02-29 | |||
| 2021-09-30 | $3.92M 10-Q · filed 2022-11-08 | $9.16M derived: sum of 2 quarters · filed 2022-11-08 | $14.00M derived: sum of 3 quarters · filed 2022-11-08 | |
| 2021-06-30 | $5.24M 10-Q · filed 2022-11-08 | $10.08M derived: sum of 2 quarters · filed 2022-11-08 | ||
| 2021-03-31 | $4.83M 10-Q · filed 2022-11-08 | |||
| 2020-12-31 | $20.50M 10-K · filed 2023-03-01 | |||
| 2020-09-30 | $4.37M 10-Q · filed 2021-11-09 | $10.88M derived: sum of 2 quarters · filed 2021-11-09 | $16.16M derived: sum of 3 quarters · filed 2021-11-09 | $20.46M derived: sum of 4 quarters · filed 2022-03-11 |
| 2020-06-30 | $6.51M 10-Q · filed 2021-11-09 | $11.79M derived: sum of 2 quarters · filed 2021-11-09 | $16.09M derived: sum of 3 quarters · filed 2022-03-11 | $20.38M derived: sum of 4 quarters · filed 2022-03-11 |
| 2020-03-31 | $5.28M 10-Q · filed 2021-11-09 | $9.58M derived: sum of 2 quarters · filed 2022-03-11 | $13.87M derived: sum of 3 quarters · filed 2022-03-11 | $17.90M derived: sum of 4 quarters · filed 2022-03-11 |
| 2019-12-31 | $4.29M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $8.59M derived: sum of 2 quarters · filed 2022-03-11 | $12.62M derived: sum of 3 quarters · filed 2022-03-11 | $17.30M 10-K · filed 2022-03-11 |
| 2019-09-30 | $4.29M 10-Q · filed 2020-11-06 | $8.33M derived: sum of 2 quarters · filed 2020-11-06 | $13.00M 10-Q · filed 2019-11-08 | $16.91M derived: sum of 4 quarters · filed 2021-03-15 |
| 2019-06-30 | $4.03M 10-Q · filed 2020-11-06 | $8.71M 10-Q · filed 2019-08-09 | $12.62M derived: sum of 3 quarters · filed 2021-03-15 | $16.52M derived: sum of 4 quarters · filed 2021-03-15 |
| 2019-03-31 | $4.67M 10-Q · filed 2020-11-06 | $8.58M derived: sum of 2 quarters · filed 2021-03-15 | $12.49M derived: sum of 3 quarters · filed 2021-03-15 | $16.69M derived: sum of 4 quarters · filed 2021-03-15 |
| 2018-12-31 | $3.91M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | $7.82M derived: sum of 2 quarters · filed 2021-03-15 | $12.01M derived: sum of 3 quarters · filed 2021-03-15 | $16.68M 10-K · filed 2021-03-15 |
| 2018-09-30 | $3.91M 10-Q · filed 2019-11-08 | $8.10M derived: sum of 2 quarters · filed 2019-11-08 | $12.77M 10-Q · filed 2019-11-08 | $16.95M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-06-30 | $4.20M 10-Q · filed 2019-08-09 | $8.86M 10-Q · filed 2019-08-09 | $13.04M derived: sum of 3 quarters · filed 2020-03-16 | $17.20M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-03-31 | $4.67M 10-Q · filed 2019-05-10 | $8.85M derived: sum of 2 quarters · filed 2020-03-16 | $13.00M derived: sum of 3 quarters · filed 2020-03-16 | |
| 2017-12-31 | $4.18M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $8.34M derived: sum of 2 quarters · filed 2020-03-16 | $17.09M 10-K · filed 2020-03-16 | |
| 2017-09-30 | $4.16M 10-Q · filed 2018-11-09 | $12.90M 10-Q · filed 2018-11-09 | ||
| 2017-06-30 | $8.75M 10-Q · filed 2017-08-09 | |||
| 2016-12-31 | $15.12M 10-K · filed 2019-03-15 | |||
| 2015-12-31 | $12.81M 10-K · filed 2018-03-14 | |||
| 2014-12-31 | $9.28M 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |